Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorAthanassiadis, A.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorDombros, N.en
dc.contributor.authorIoannidis, I.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorSkarlos, D.en
dc.date.accessioned2015-11-24T19:00:09Z
dc.date.available2015-11-24T19:00:09Z
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19489
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents, Phytogenic/administration & dosageen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBreast Neoplasms/drug therapyen
dc.subjectCarboplatin/administration & dosageen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosageen
dc.subjectTreatment Outcomeen
dc.titlePaclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Groupen
heal.abstract37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg.min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9470853-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0959804997002177/1-s2.0-S0959804997002177-main.pdf?_tid=c05cf71f66786220ccc70ef1be82312d&acdnat=1333703082_1dfdceb058d4d7c2a393a57f85189247-
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1997-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ